Pfizer Inc. (NYSE:PFE) is among the 13 Best Dividend Stocks Paying Over 6%. UBS initiated coverage of Pfizer with a Neutral rating and $25 price target due to uncertainty around revenue outlook. Pfizer announced a new AI-focused partnership with Boltz, PBC to enhance biomolecular AI models for drug development.

Boltz, known for open-source biomolecular models, will refine models using Pfizer’s data, creating exclusive next-gen models for drug design. Pfizer retains ownership of compounds developed with Boltz’s support. Pfizer is a global biopharmaceutical company focused on discovering, developing, and commercializing medicines and vaccines worldwide.

While Pfizer shows investment potential, some AI stocks may offer greater upside with less risk. For an undervalued AI stock with potential benefits from Trump-era tariffs and onshoring trend, see our free report on the best short-term AI stock. Check out 12 Best Dow Stocks to Buy in 2026 and 13 Best Consumer Staples Dividend Stocks to Invest In Now. No disclosure.

Read more at Yahoo Finance: UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE